Harnessing oncolytic viruses for cancer immunotherapy to improve treatment outcomes

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

FDA approved PDE4 inhibitor roflumilast for atopic dermatitis

On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions

July 12, 2024

Hospitals Show Signs of Recovery, But Growth Strategies Crucial for 2024 Success

What You Should Know: – A glimmer of hope shines through for hospitals, according to November data from Kaufman Hall’s National Hospital Flash Report points

January 10, 2024

Opinion | Paul Offit on the Causes and Legacy of COVID Misinformation

Jeremy Faust is editor-in-chief of , an emergency medicine physician at Brigham and Women’s Hospital in Boston, and a public health researcher. He is author

March 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.